Groundbreaking new study links 25 genes to Obsessive Compulsive Disorder
A new study has found 25 genes believed to cause Obsessive Compulsive Disorder.
More than 50,000 people with the condition had their genetic data compared to those who did not.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
6 hours ago
- News.com.au
Scott Power: ASX health stocks dip but it was a good news week for EMVision
ASX health stocks dipped 0.82% over the past five days while the broader market has risen 1.26% EMVision appoints Ramsay Health Care CEO to board and expands sites of pivotal trial First Japan site opens for Dimerix's phase III clinical trial of DMX-200 in rare kidney disease Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week and his 'Powerplay' stock pick. Power said that, while healthcare markets were down this week, broader markets remained elevated with things starting to look more positive at the halfway mark of a thus-far volatile 2025. US President Donald Trump's trade and health policies have been impacting the sector throughout the year. At about lunchtime on Friday the S&P/ASX 200 Health Care index was down 0.82% for the past five days, while the benchmark ASX 200 rose 1.26% for the same period. "The broader market is up this week and May was a reasonably good month," he said. "We are coming up to June 30 and the end of financial year so there will be some tax-loss selling coming through across various portfolios. "June tends to be a weaker month as investors look to clean up their portfolio, while July seasonally tends to be a stronger month and there is potentially some good value out there across the smaller names which really haven't done too much for the last couple of years." Ramsay CEO joins EMVision board, trial expands EMVision Medical Devices (ASX:EMV) has had two major announcements this week including the appointment of Ramsay Health Care (ASX:RHC) CEO Carmel Monaghan as non-executive director and broadening of a pivotal trial for its emu bedside brain scanner, which is designed to rapidly diagnose stroke. Monaghan has worked across hospital, corporate and global positions at Ramsay for almost three decades. "She is highly regarded and will bring a lot of credibility and contacts into the business," Power said. He said EMvision was also making good progress with the activation of its third US site, Mount Sinai Hospital in New York, scheduled for this month. Activation of its second Australian site, Liverpool Hospital in Sydney, has also been in progress this week. Five world-leading hospitals in stroke care are now taking part in EMVision's pivotal trial with a sixth set to be activated shortly. The pivotal (validation) trial is designed to support US Food and Drug Administration (FDA) de novo (new device) clearance of the emu point-of-care brain scanner device. "The expectation is that they will get approval sometime in 2026," Power said. Power's Powerplay: Big year for Dimerix Dimerix (ASX:DXB) is Power's stock of the week after announcing it had opened the first trial site in Japan for its ACTION3 phase III drug candidate DMX-200 to treat focal segmental glomerulosclerosis (FSGS) kidney disease. Opening of Japan's first clinical trial site for ACTION3 triggers the first development milestone payment of ¥400 million (~A$4.3m) to Dimerix from FUSO Pharmaceutical Industries Ltd, its exclusive licensee of DMX-200 for FSGS in Japan. FUSO is one of four regional licensing deals executed for DMX-200, which collectively provide up to ~$1.4bn in total upfront payments and potential milestone payments, plus royalties on net sales. FSGS is a serious kidney disease that causes progressive scarring, leading to permanent damage and, ultimately, end-stage kidney failure – often requiring dialysis or a transplant. It affects adults and children and no treatments are currently approved specifically for the condition anywhere in the world, affecting overall prognosis. As a result, DMX-200 has received orphan drug designation in both the US and Europe, along with the UK's equivalent designation under the Innovative Licensing and Access Pathway (ILAP). Dimerix last year reported positive interim results from the ACTION3 trial, showing DMX-200 was performing better than placebo in reducing proteinuria with no safety concerns to date. Full enrolment in the ACTION3 study is expected by the end of 2025 with a further blinded interim analysis planned. "It's going to be a big year for Dimerix," Power said. Mayne Pharma takeover deal far from over Adelaide-headquartered pharmaceutical company Mayne Pharma (ASX:MYX) is continuing to do battle with its US-based suitor Cosette Pharmaceuticals after announcing on Wednesday it had received a notice "purporting to terminate" the $7.40 per share offer worth more than $600 million. The withdrawal comes after Cossette asserted that a "material adverse change" had occurred, and consequently freeing Cosette from its obligations under the scheme implementation deed (SID). The announcement sent the stock lower and came hours after Mayne put out another one telling the market it had not received a notice of termination, which sent its shares higher. On Thursday Mayne put out another announcement saying the scheme meeting would go ahead on June 18, as scheduled with the stock rising more than 7%. "Mayne Pharma directors continue to unanimously recommend that vote in favour of the scheme resolution at the scheme meeting, in the absence of a superior proposal," said chairman Frank Condella. However, the company needs a court decision to affirm its view that the "material adverse change" were not, in fact, material. "There is a fair bit more water to flow under the bridge with this one and it just looks very messy at the moment," Power said. ReNerve enters partnership to expand product range Biotech company ReNerve (ASX:RNV) this week announced it had entered a strategic partnership with US-based Berkeley Biologics LLC to develop and commercialise two new complementary tissue-based product ranges. The first range addresses the need for human dermal tissued, deeper layers of the skin often sourced from donors. The second product range will provide amniotic tissue products, which are known for their regenerative and healing properties. The products are set to be produced at Berkeley Biologics' California facility and launch before the end of CY25. ReNerve said the new products represent a natural extension of its existing sales activities, leveraging the same sales network and continuing to target the same surgeon and hospital customer base. The company said surgeons could incorporate additional tissue grafts when treating nerve injuries, enabling them to address both the damaged nerve and any associated trauma. "It is a strong indication that they're trying to build their sales momentum by expanding the product offering to the surgeons," Power said. "Sales are expected to grow over subsequent quarters." The views, information, or opinions expressed in the interview in th is article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article.
ABC News
6 hours ago
- ABC News
Actor and disability advocate Chloé Hayden is learning to prioritise what matters
Unwind with… is a regular column that explores the simple ways interesting people take care of themselves through periods of change or upheaval. Actor and disability advocate Chloé Hayden lives in regional Victoria on Wadawurrung Country. The 27-year-old stars as Quinni on Heartbreak High, with the show's third and final season streaming this year. Chloé says the entertainment industry is exciting to work in, but it's "also really difficult when you're neurodivergent and rely so heavily on routine". Chloé was diagnosed as autistic in her adolescence and lives with postural orthostatic tachycardia syndrome (POTS), endometriosis and adenomyosis. "I'm a lot better at looking after and respecting my neurodivergent brain," she says. "I don't yet have the same grace for a sick body." But she's learning to rest and make room for what she loves beyond work. When I go out to be with my horses is probably when I feel the happiest. Or, when I let myself relax. Not the pretend relaxing where I'm telling my body that we're relaxing but my brain is going over a million things that I must do or that I'm feeling ...when I'm just reading a book or playing a video game, truly being-in-the-moment relaxing. Since getting [the role of Quinni], my horses were put on the back burner. That was very scary and honestly caused a pretty big identity crisis. I'm a competitive horse rider and I can't train my horses up knowing that I might have to [be called back to work before a competition]. I just went,"well, I guess I just won't do anything with them because there's too much emotion and heartbreak if I have to [leave for work] again". I was then really confused when I was sad and anxious all the time. I sat down and I spoke to some people, and I realised that there was no reason why I couldn't have both. I just wasn't prioritising things that I needed to prioritise. I'm still trying to figure it out and learn when I need to stop. I'm also trying to learn when I need to accept help from other people. I know what does help is switching off and respecting when my body is giving me signals to stop and taking that time off to rest. Lying on the couch with my cats all over me and playing a video game and letting my husband look after me completely, giving in to going "you're not broken or wrong, you don't hold less value or worth because you're letting someone help you out". I can't cook to save myself, but my husband knows my safe [comfort] foods. My mum's dal recipe is a big safe food. If I'm having a shitty day, he usually knows before I do. He'll make sure that I'm eating and drinking throughout the day because it will get worse if I'm not looking after my physical body. I love being in the bush, I love having open fields around me, I love being away from everyone and being able to see the stars at night and being able to have all of my horses surrounding me. You couldn't convince me to ever live in the city.
News.com.au
6 hours ago
- News.com.au
South Australian treasurer Stephen Mullighan announces new $28m AI program in state budget
The coming AI tidal wave is beginning to hit into Australia's public sector, with the South Australian government announcing a new $28m program to embed the technological revolution into policing, healthcare, finance and law. Treasurer Stephen Mullighan delivered the surprise allocation in the state's 2025-26 budget, with the funding designed to 'maximise on the benefits and promote growing the use of AI applications across the South Australian public sector'. The budget measures claim the program will initially prioritise policing and healthcare with a set of 'proof of value trials'. 'Through targeted proof of value trials in priority areas such as health care and policing, this funding will provide support for broad applications across government and allow multiple use cases to be developed on trusted foundational technologies, with appropriate governance and alignment to the investment principles of the digital investment fund,' the document says. 'The health sector is a priority for funding consideration, as global evidence shows that integrating AI in specific areas of healthcare can reduce costs and improve operational efficiency, allowing healthcare professionals to spend more time on clinical care.' In policing, the program will look to enhance efficiency and safety for officers. 'AI can be used to support real-time decision making to help allocate resources effectively, increase officer and public safety and reduce administrative burden on officers, freeing up time for more value-added work,' the document states. 'Other areas considered for priority funding may include allied health, social work and legal and financial areas of the public sector.' The program, which sits within the government's broader digital investment fund, is funded from 2025-26 through to 2028-29, with an estimated $4.6m in yearly operating expenses and $2.4m in yearly investing expenses. Twenty full time jobs are expected to deliver the program over the period. South Australia's explicit support for AI comes as all jurisdictions grapple with the promise and peril of AI. In February this year, Queensland Information Commissioner Joanne Kummrow warned taking a 'wait and see' approach to AI risked the public sector 'falling behind understanding and responsibly engaging with its capabilities and challenges'. 'While AI shows promise as a powerful tool capable of delivering improved public services, agencies need to take the 'right path' by mitigating privacy and security risks and ensuring its ethical and transparent use, rather than taking the 'fast lane' without due regard to the necessary guard rails and protection of citizens' personal information,' she posted to the website of the Office of the Information Commissioner. The NSW government, meanwhile, funnelled more than $2.7m in grants to 16 councils in mid 2024 to trial AI in local planning systems. The trials were designed to 'improve the development application process for all users, including homeowners, councils and developers'. Outside of government, South Australia will also deploy AI to develop a fuller picture of its mineral wealth, with a particular focus on copper production in the giant Gawler Craton, which sprawls across the central portion of the state.
